Opioid prescribing in out-of-hours primary care in Flanders and the Netherlands: A retrospective cross-sectional study | PLOS ONE
![Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes | Business Wire Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes | Business Wire](https://mms.businesswire.com/media/20211027005515/en/739014/23/teva_RGB_JPEG.jpg)
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes | Business Wire
![European Commission investigation into Teva's potential abuse of dominance – misuse of patent procedures and disparagement - Allen & Overy European Commission investigation into Teva's potential abuse of dominance – misuse of patent procedures and disparagement - Allen & Overy](https://www.allenovery.com/global/-/media/allenovery/people/m/molestina_julia-3038921_web.jpg?rev=3fd0fcb4764b4aad969521d68d7de7f2&h=854&w=1366&la=en-GB&hash=95BA6800C33C289C3478106094D98C19)
European Commission investigation into Teva's potential abuse of dominance – misuse of patent procedures and disparagement - Allen & Overy
![Polpharma Biologics Group Announces That Its Joint Venture Company, Bioeq, Has Entered Into a Commercialization Agreement for Biosimilar Ranibizumab | Business Wire Polpharma Biologics Group Announces That Its Joint Venture Company, Bioeq, Has Entered Into a Commercialization Agreement for Biosimilar Ranibizumab | Business Wire](https://mms.businesswire.com/media/20210707005415/en/889874/23/Logotype-Polpharma_Biologics_%282%29.jpg)